BNT211 already has orphan drug and fast-track ... at approximately 35%. BioNTech and Regeneron are competing with rivals Moderna and MSD in the mRNA melanoma jab category, with the latter a ...
“BioNTech’s achievements during the period were the successful ... where the safety profile was manageable and encouraging clinical activity was observed. Cell Therapy Programs BNT211 consists of a ...
16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...
The validity of the patent is at the heart of patent litigation between CureVac and fellow German biotech BioNTech and its partner Pfizer, claiming infringement by their Comirnaty coronavirus shot.
Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine uptake, pricing and seasonal variations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback